NASDAQ: AVRAnteris Technologies Global Corp Stock
$5.66+0.08 (+1.43%)
Updated Apr 27, 2026
AVR Price
$5.66
Fair Value Price
-$1.21
Market Cap
$550.33M
52 Week Low
$2.85
52 Week High
$6.95
P/E
-2.22x
P/B
-5,917.56x
P/S
107.47x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.91M
Earnings
-$94.14M
Gross Margin
70.3%
Operating Margin
-4,917.46%
Profit Margin
-4,921.3%
Debt to Equity
-250
Operating Cash Flow
-$78M
Beta
1.71
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AVR Overview
Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AVR's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
AVR
Ranked#39 of 41
Ranked#39 of 41
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.66 | A | |
| $9.24 | A | |
| $26.77 | A |
Be the first to know about important AVR news, forecast changes, insider trades & much more!
AVR News
Overview
Due Diligence Score
–
Industry Average (31)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AVR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AVR ($5.66) is overvalued by 567.39% relative to our estimate of its Fair Value price of -$1.21 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AVR ($5.66) is not significantly undervalued (567.39%) relative to our estimate of its Fair Value price of -$1.21 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AVR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AVR due diligence checks available for Premium users.
Valuation
AVR fair value
Fair Value of AVR stock based on Discounted Cash Flow (DCF)
Price
$5.66
Fair Value
-$1.21
Undervalued by
567.39%
AVR ($5.66) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AVR ($5.66) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AVR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AVR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.22x
Industry
-519.39x
Market
35x
AVR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-5,917.56x
Industry
3.48x
AVR's financial health
Profit margin
Revenue
$310.0k
Net Income
-$29.2M
Profit Margin
-9,420%
AVR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AVR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$23.0M
Liabilities
$23.3M
Debt to equity
-250
AVR's short-term liabilities ($21.37M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AVR's short-term assets ($15.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AVR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AVR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.5M
Investing
-$397.0k
Financing
$22.4M
AVR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AVR vs Medical Stocks
Anteris Technologies Global Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.